Long-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis

Adelina Yafasova, Emil L Fosbøl, Morten Schou, Finn Gustafsson, Kasper Rossing, Henning Bundgaard, Marie D Lauridsen, Søren L Kristensen, Christian Torp-Pedersen, Gunnar H Gislason, Lars Køber, Jawad H Butt

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

12 Citationer (Scopus)
1 Downloads (Pure)

Abstract

BACKGROUND: It is estimated that 5% of patients with sarcoidosis have clinically manifest cardiac involvement, although autopsy and imaging studies suggest a significantly higher prevalence of cardiac involvement. There is a paucity of contemporary data on the risk of adverse cardiac outcomes, particularly heart failure (HF), in patients with sarcoidosis.

OBJECTIVES: The purpose of this study was to examine the long-term risk of HF and other adverse cardiac outcomes in patients with sarcoidosis compared with matched control subjects.

METHODS: In this cohort study, all patients age ≥18 years with newly diagnosed sarcoidosis (1996 to 2016) were identified through Danish nationwide registries and matched 1:4 by age, sex, and comorbidities with control subjects from the background population without sarcoidosis.

RESULTS: Of the 12,042 patients diagnosed with sarcoidosis, 11,834 patients were matched with 47,336 subjects from the background population (median age: 42.8 years [25th to 75th percentile: 33.1 to 55.8 years], 54.3% men). The median follow-up was 8.2 years. Absolute 10-year risks of outcomes were as follows: HF: 3.18% (95% confidence interval [CI]: 2.83% to 3.57%) for sarcoidosis patients and 1.72% (95% CI: 1.58% to 1.86%) for the background population; the composite of ICD implantation, ventricular arrhythmias, and cardiac arrest: 0.96% (95% CI: 0.77% to 1.18%) for sarcoidosis patients and 0.45% (95% CI: 0.38% to 0.53%) for the background population; the composite of pacemaker implantation, atrioventricular block, and sinoatrial dysfunction: 0.94% (95% CI: 0.75% to 1.16%) for sarcoidosis patients and 0.51% (95% CI: 0.44% to 0.59%) for the background population; atrial fibrillation or flutter: 3.44% (95% CI: 3.06% to 3.84%) for sarcoidosis patients and 2.66% (95% CI: 2.49% to 2.84%) for the background population; and all-cause mortality: 10.88% (95% CI: 10.23% to 11.55%) for sarcoidosis patients and 7.43% (95% CI: 7.15% to 7.72%) for the background population.

CONCLUSIONS: Patients with sarcoidosis had a higher associated risk of HF and other adverse cardiac outcomes compared with matched control subjects.

OriginalsprogEngelsk
TidsskriftJournal of the American College of Cardiology
Vol/bind76
Udgave nummer7
Sider (fra-til)767-777
ISSN0735-1097
DOI
StatusUdgivet - 2020

Bibliografisk note

Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Citationsformater